Differential CD44 expression patterns in primary brain tumours and brain metastases. by Li, H. et al.
BrUs JomidC amc w n(135) 72 160-163
x ©-c) 1995 Stoktn Pre Al rits rserved0007-0920/95$12.00
Differential CD44 expression patterns in primary brain tumours and brain
metastases
H Li"2, J Liu"-2, M Hofmann3, M-F Hamou2 and N de Tribolet2
'Divsion of Molecular Biology, Shenyang Medical College, 110031 Shenyang, People's Republic ofChina; 25ervi of
Neurosurgery, University Hospital, 1011 Lausne, Switzerland; 3German Institute ofGenetics, KarLsruhe, D-76021, Germy.
Smary Spicing variants of CD44 (CD44v) are increasingly recognised as metastasis-promoting factors in
rodent and some human caners However, the frequency for CD44v exprson in human ars and their
metastases and the status ofCD44v xpession in low or non-metastatic tumours is still uncertain. To addres
this issue, we investigated CD44 expression patterns in brain asta (BMTs) spread from more than ten
organs and five types of primary baintumours (PBTs) by Northen blot, reve n r n-polymera
chain reactio (RT-PCR) and immunocytochenical analysis. The results denlmstrated that all of the 56
PBTs eamined express standard form of CD44 (CD44s) but none of them express CD44v. In contrst, 22 of
26 BMTs studied were found with CD44v expesson. Our data thus present dit eviden of a general
distribution of CD44 in BMTs but sugget that such expresson is an extremely rare event in PBTs Tberefore,
the presesce or absence of CD44v expression may be related to high or low metastatic potential of human
ignanies.
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Recently, a new member appeared in the list of metastasis-
related genes: CD44v, a series of isoforms of the lymphocyte
homing receptor/epithelial adhesion molcule CD44. Its close
correlation with metastasis was underlined by the abilty to
confer metastatic potential on low or non-metastatic rat pan-
creatic cancer cells (Gunthert et al., 1991) and the high
incidence of CD44v expresson in several types of human
cancers and their metastases (Hofmann et al., 1991; Mat-
sumura and Tarin, 1992; Heider et al., 1993a,b). So far, the
underlying mechanisn of CD44v-mediated astais is
largely uninown, but it is hypothesised that metastatic cells
with CD44v expression mimic crculating lymphocytes during
their dissinaton to lymph nodes (Arch et al., 1992), allow-
ing metastasing tumour cell to bind to a not yet identified
ligand in the distant blood and lymphatic vessels.
In the literature, most studies concerning CD44v expres-
sion in human cancer cells and its correlation with metastasis
have been performed on adenocarcinomas of the breast,
colon and stomach (Matsumura and Tarin, 1992; Heider et
al., 1993a, Mayer et al., 1993; Wielenga et al., 1993). We
reported previously the absence of CD44v expression in
highly invasive but rarely metastatic glioblastomas (Li et al.,
1993). However, so far no comprehensive analysis of CD44v
status in low- and non-metastatic human malignancies has
been performed. Thus, it is not certain whether CD44v
expression is a general feature of tumours with metastatic
potential or merely a cell type-specific expression. Nor has it
been established whether rarely metastatic or non-metastatic
tumours lack CD44 expression. To address this issue, we
compared CD44 expression patterns in five types of prinary
brain tumours which rarely metastasise and in brain meta-
stases derived from ten different organs.
Materia and metods
Sample collection
The samples used in this study were 27 brain metastases
which originated from more than ten organs with different
morphology (Table I), 17 surgical specimens of glioblas-
tomas, eight benign and two malignant meningomas, 13
neurinomas, 12 nmduloblastomas and four ependymomas.
The tumour samples were collected directly from the oper-
ation room, and parts of the tumours were frozen in liquid
nitrogen within 2 h of removal, and stored at -70-C until
use. The emnaining parts were fixed in 10% buffered for-
main, and embedded in paraffin for conventional his-
topathological examination.
RNA isoation andanalyses
Total celular RNA was isolated from the tumour sampls
and cell lines by the method of Chomczynski and Sacchi
(1987). Northern blot analysis was done with a 1.5 kb cDNA
probe encompassing both standard and variant CD44
sequences (Hofnann et al., 1991). A spontaneously immor-
talised human keratinocyte line, HaCat (Hofmann et al.,
1991), was used as positive control for splicing variants of
CD44 in the experiments.
To confirm the results from Northern analysis, RNA
samplesex racted from 22 brain metastases (BMTs) and some
representative cases of each kid of pinmary brain tumours
(PBTs) were subjected to RT-PCR. Random primers were
used for first-stad cDNA synthesis and sense upstream
(5'-CAGACCTGCCCAATGCCTITGATGGGAC) and an-
tisense downstream (5'-CAAAGCCAAGGCCAAGAGGGC-
TGCC) prmers were used for PCR amplfication. These
primers flank- the highly variable extracellular region, where
additional exons can be 'inserted' by alternative spling
(Tolg et al., 1993). The reverse transcription reaction was
performed at 3TC for 60min, followed by incubation at
95C for 5 min to inactivate the reverse transcriptase. PCR
was done with the following parameters: 94 C for 5 min, then
Table I Detection of CD44 mokeuks in PBTs and BMTs
CD44 expression
Tumour CD44s CD44v
Glioblastoma mulftiformes 17/17 0/17
Meningiomase 10/10 0/10
Neurinomas 13/13 0/13
Medulloblaomasb 12/12 0/12
Ependymomas 4/4 0/4
Brain metastases 21/22 22/26
aEight benign, twomalignant. bNon-metastatic.
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92'C for 40 s; 60°C for 40 s and 74°C for 90 s for 35 cycles,
and finally, 75'C for 5 min. For Southern blot analysis, the
PCR products were resolved by electrophoresis on 1.4%
agarose gel, transferred to hybond N+ nylon membrane
(Amersham, UK) and hybridised with [_-32PjdATP-labelled
probes specific for exons v8-vlO. After washing and
exposure, the filter was stripped by incubation in boiled
distilled water for 1-2h and rehybridised with a cDNA
probe for exons v6/v7, providing identification of CD44s and
CD44v (Hofmann et al., 1991) respectively.
Imimmocytochemical stainings
In order to show differential CD44 expression at protein level
and rule out the possibility of post-translational modification
including epitope masking, immunocytochemical staining was
performed on frozen sections of 26 brain metastases and all
primary brain tumours. A monoclonal antibody detecting
both CD44s and CD44v (Oncogene Science, Uniondale, NY,
USA) and a polyclonal antibody against CD44v (a generous
gift from Karl-Heinz Heider, Germany) were used for screen-
ing the existence of CD44s and CD44v. For the CD44v-
positive cases, CD44 moleule expressed in those tumours
were further characterised with four monoclonal antibodies
(MAbs) speificaly recognising the epitopes encoded by
variable spliced exons vS (VFF-8), v6 (VFF-7), v7 (VFF-9
and -17) and v8-vlO (VFF-14) (Mackay et al., 1994).
Keratnocytes in a normal skin section were used as positive
control for CD44v. The results were compared with that
obtained from Northern and RT-PCR-Southern analyses.
Results
Northern hybridisation revealed that 17 glioblastoma cases,
ten meningiomas, 13 neurinomas, four ependymomas and 12
medulloblastomas express CD44 RNAs which were uniform
in size, 5.0 kb, 2.2 kb and 1.8 kb, corresponding to CD44s
transcripts (Li et al., 1993). In contrast, heterogeneous
hybridisation patterns were observed among 22 brain meta-
stases: one was completely negative for CD44 expression, two
were similar to that of PBTs, while 19 showed enlarged
CD44 transcripts. In the last cases, six showed a similar
hybridisation pattern to HaCat cells which express a CD44v
RNA encompassing exons v3-vlO. In comparison with
HaCat, the remaining 13 cases gave smaller transcripts which
hybridised with specific probes for exons v4/v5 and v6/v7 or
v8-vlO only or both. The incidence of CD44 and CD44v
detection in all of the tumour groups was 100% CD44s and
0% CD44v in 56 PBT samples, and 95% CD44s and 86%
CD44v in 26 BMT samples (Table I). Patient numbers and
the origins, histologies and CD44 expression patterns of
brain metastases are listed in Table II.
In parallel with the data of Northern blot hybridisation,
the results of RT-PCR (Figure 1) demonstrated that, when
the filters were hybridised with the exon v8-vlO-specific
probe, only a proportion of BMTs were positive, in the form
of three main bands ranging from 800 bp to 1.4 kb. When
the same filter was rehybridised with the probe for exons
v6/v7, 17 out of 19 cases with enlarged transcripts in North-
ern blot gave a positive hybridisation. No hybridisation of
CD44v could be found among the PBT samples. When the
same filter was rehybridised with the 1.5 kb cDNA probe of
CD44, the samples from both BMTs and PBTs revealed a
strong 409 bp band corresponding to the PCR product of
CD44s.
Immunocytochemical staining showed that all PBTs
studied were positive for CD44, but no positive staining for
any form of CD44v could be observed. In contrast, the
staining could be detected in 22 out of 26 brain metastases
with either anti-CD44s/v antibody or anti-CD44v antibody.
However, BM-712 and BM-678, which gave positive hyb-
nrdisation for CD44s in Northern and RT-PCR, was
negative in immunohistochemistry, indicating possible con-
tamination of tumour RNA by normal tissues expressing
CD44s, e.g. gliosis. CD44 molecules expressed by those 22
positive cases were further characterised with four MAbs
specifically recognising the epitopes encoded by variably
spliced exons v5, v6, v7 and v8-vlO. It was found that 13
cases were positive for exons v5-vlO (Figure 2a), six were
positive for exons v5-v7 but not for exons v8-vlO (Figure
2b) and three were positive for exons v8-vlO but almost
negative for exons v5-v7 (Figure 2c). These results are in
good agreement with those obtained in Northern and
RT-PCR analyses (Table II).
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Table H Distribution of CD44v isoforms in brain metastases with different origins
Case no. CD44v (+j v-exons
Origin Histology (+) rates (sex/age) RNA IC 3 415 6/7 8 9/10'
Lungs Squamous 4/4 312 (M, 57) ND + + + + + +
492 (F, 68) + + + + + + +
667 (M, 58) + + + + + + +
799 (M, 62) + + + + + + +
Adenocarcinoma 3/4 375 (M, 64) + + +
643 (M, 54) + + +
671 (M, 52) + + + + + + +
712 (M, 53) - - (-)
SCLCb 0/2 678 (M, 55) - _ (-)
681 (M, 51) - - (_)
LCLCb 1/1 544 (M, 44) + + + +
Breast Adenocarcinoma 6/6 527 (F, 65) ND + + + + +
663(F, 58) + + + + + +
710 (F, 56) + + + +
725(F, 58) + + + +
778(F, 70) + + + + + +
836 (F, 51) + + + + + +
Testis Adenocarcinoma 2/2 687 (M, 51) + + + +
748 (M, 50) ND + + +
Cervix Squamous 1/1 345 (F, 56) + + + + + + +
Tonsil Squamous 1/1 532 (M, 63) + + + + + + +
Colorectum Adenocarcinoma 2/2 395 (M, 60) + + + +
863 (F, 53) + + + +
Histiocyte Histiocytoma 1/1 733 (F, 58) + + + + + +
Skin Melanoma 1/1 463 (M, 66) + + + + + +
Kidney Adenocarcinoma 0/1 318 (M, 61) ND - (-)
Positive rates 22/26 (84%) 19/22 22/26
av3, domain I; v4/v5, II; v6/v7, HI; v8, IV; v9/vlO, V. bSCLC, small-cell lung cancer, LCLC, large-cell lung cancer.
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Fgwe 1 Representation ofdifferential CD44 expression patterns
in human brain metastases (BMs) and primary brain tumours
(PBTs). HaCat, the positive control for CD44 v3-vlO. BMs. 1, a
squamous cell carinoma of the tonsil (no. 532); 2, an adenocar-
cinoma of the lung (no. 375); 3, an of the breast
(no. 710); 4, a squamous cel car of the lung (no. 667) and
5, a small-cell hmg cancer (no. 681). PBTs G, a case of glioblas-
toma; M, menngio N, neurinoma; Md, medulloblasoma;
and E, ependymoma.
The current study provides further evidence for the rarity of
CD44v expression in primary brain tumours, suggesting that
lack ofCD44 variants may be ofbiological signifin in the
low propensity of these tumours to metastasise. This study
does not exclude the possibility that CD44s, as a
hyaluronate-binding adhesion molecule, may play a role in
local tumour invasion and spreading, since hyaluronate is a
major component of brain extracellular matrix (Asher and
Bignami, 1992). However, the variable invasive behaviour of
PBTs suggests that this may be the case only after additional
genetic event(s) have occurred, increasing the malignancy of
the cells. Additionally, our data imply that CD44v may not
be necessary for brain tumour invasion because of its absence
in highly invasive glioblastomas.
According to the literature, CD44v is expressed con-
stitutively in squamous ceUs of normal bronchial, cervical
and tonsil mucosa, but not in normal epithelial cells in the
colon, lung and breast (Heider et al., 1993a; Mackay et al.,
1994), demonstrating a cell type-specific expression of CD44v
in normal epithelial cells. In contrast, CD44v becomes detect-
able in metastatic tumours including brain metastases formed
by adenocarctnomas of the breast (6/6), the lung (3/4) and
digestive tract (2/2), supporting the idea that CD44v expres-
sion is acquired during progression of human adenocar-
cinomas (Heider et al., 1993b). Furthermore, our results
demonstrate that, as well as keratinocytes grown in vivo and
in vitro, aUl brain metastases of squamous cell origin exp-
ressed full-length CD44v, ruling out possible instability or
down-regulation of CD44v expression after malignant trans-
formation of squamous epithelial cells (Salmi et al., 1993).
As shown in Table II, CD44v is distributed in 84% of
various kinds of brain metastases with different morphologies
and its expression pattern is heterogeneous: squamous cell
carcinomas, irrespective of origin from the lungs, tonsil or
cervix, express mainly CD44v containing exons v3-vlO,
while adenocarcinomas express multiple isoforms with exons
v4-v7, v8-vlO or v3-vlO. Since exons v4-v7 are found to
exist in most of the tumours studied, it is possible that these
dI
Fugwe 2 Immunocytochemical stainings with the monoclonal
antibodes against CD44v exon 5, VFF-8 (left) and exons 8-10,
VFF-14 (right). (a) Brain meass oniginatng from a squamous
cell carcinoma of the cervix (BM-345). (b) Brain meastasis
formed by of the hmgs (BM-643). (c) A brain
metastasis formed by a large cel lung cancer (BM-544). (d)
Normal skin as positive control for both v5 and v8-vlO.
BMsCD"expression braintumours
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exons may be the structural and even functional core part of
CD44v. Absence of CD44s and CD44v expression in the
remaining 16% of brain metastases formed by small-cell lung
cancers, adenocarcinomas of the lungs and kidney implies the
existence of CD44v-independent metastatic pathways which
may be mediated by other genetic alterations.
In summary, our data present direct evidence for general
distribution of CD44v in various kinds of human tumours
metastasising to the brain and show that expression of
CD44v is an extremely rare event in five types of PBTs,
indicating that CD44v may be one of the important elements
for tumour cells to metastasise.
Abbreviatios: CD44s, standard form of CD44; CD44v, splicing
variants of CD44; RT-PCR, reverse transcription-polymerase chain
reaction.
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